Brad Prechtl, MBA
Chief Executive Officer
As Chief Executive Officer of Florida Cancer Specialists, Brad Prechtl is responsible for developing and implementing the organization’s mission to provide world-class cancer care in community-based settings close to home. As a nationally recognized healthcare executive with over 30 years of experience, Brad guides the continued growth of FCS – while maintaining the highest standards in clinical care.
Brad joined FCS in 2009, bringing more than 20 years of physician practice management experience. He spent seven years as CFO and CEO of several PhyCor multi-specialty physician practices, as well as seven years at US Oncology. During his tenure at US Oncology, Brad served as the Executive Director of Practice Operations for Texas Oncology. In addition, Brad was the President of Crozer Keystone Health Network, a multi-specialty physician group practice, and COO for Physician Oncology Services, a prostate cancer treatment network in Georgia, Indiana and Kentucky.
After graduating with a bachelor’s degree in accounting and passing the CPA exam, Brad spent three years as an auditor and consultant at Big 8 firms Arthur Andersen and Coopers and Lybrand, and he earned his master of business administration (MBA) from the University of Pittsburgh, while working at the University of Pittsburgh Medical Center (UPMC).
Brad is committed to his community and serves as a volunteer with Big Brothers/Big Sisters. He also served as Chairman of the Board for the Florida Cancer Specialists Foundation from 2010 to 2018, which provides non-medical financial assistance to qualified cancer patients in Florida. Additionally, Brad served as the 2016 and 2017 Florida Chair of American Cancer Society’s CEO’s Against Cancer, a program of the American Cancer Society.
Brad and his wife, Terri, are the parents of four children and his interests include the Pittsburgh Steelers, golf and travel.
Brad Prechtl, CEO - Florida Cancer Specialists describes his role as CEO of Florida Cancer Specialists including the growth of their ancillary services such as the central lab, radiology, clinical research and oral pharmacy.